In:
Frontiers in Genetics, Frontiers Media SA, Vol. 13 ( 2022-5-3)
Abstract:
As the traditional treatment for glioma, the most common central nervous system malignancy with poor prognosis, the efficacy of high-intensity surgery combined with radiotherapy and chemotherapy is not satisfactory. The development of individualized scientific treatment strategy urgently requires the guidance of signature with clinical predictive value. In this study, five prognosis-related differentially expressed immune-related genes (PR-DE-IRGs) (CCNA2, HMGB2, CASP3, APOBEC3C, and BMP2) highly associated with glioma were identified for a prognostic model through weighted gene co-expression network analysis, univariate Cox and lasso regression. Kaplan-Meier survival curves, receiver operating characteristic curves and other methods have shown that the model has good performance in predicting the glioma patients’ prognosis. Further combined nomogram provided better predictive performance. The signature’s guiding value in clinical treatment has also been verified by multiple analysis results. We also constructed a comprehensive competing endogenous RNA (ceRNA) regulatory network based on the protective factor BMP2 to further explore its potential role in glioma progression. Numerous immune-related biological functions and pathways were enriched in a high-risk population. Further multi-omics integrative analysis revealed a strong correlation between tumor immunosuppressive environment/IDH1 mutation and signature, suggesting that their cooperation plays an important role in glioma progression.
Type of Medium:
Online Resource
ISSN:
1664-8021
DOI:
10.3389/fgene.2022.889629
DOI:
10.3389/fgene.2022.889629.s001
DOI:
10.3389/fgene.2022.889629.s002
DOI:
10.3389/fgene.2022.889629.s003
DOI:
10.3389/fgene.2022.889629.s004
DOI:
10.3389/fgene.2022.889629.s005
DOI:
10.3389/fgene.2022.889629.s006
DOI:
10.3389/fgene.2022.889629.s007
DOI:
10.3389/fgene.2022.889629.s008
DOI:
10.3389/fgene.2022.889629.s009
DOI:
10.3389/fgene.2022.889629.s010
DOI:
10.3389/fgene.2022.889629.s011
DOI:
10.3389/fgene.2022.889629.s012
DOI:
10.3389/fgene.2022.889629.s013
DOI:
10.3389/fgene.2022.889629.s014
DOI:
10.3389/fgene.2022.889629.s015
Language:
Unknown
Publisher:
Frontiers Media SA
Publication Date:
2022
detail.hit.zdb_id:
2606823-0
Permalink